TSCAN THERAPEUTICS, INC. (TCRX) Return on equity 2021–2025
TSCAN THERAPEUTICS, INC. (TCRX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-105.4%FY2025 · since FY2021: -30.2% → -105.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -105.4% | -52.5 pp |
| FY2024 | -52.9% | +6.2 pp |
| FY2023 | -59.1% | +7.5 pp |
| FY2022 | -66.6% | -36.4 pp |
| FY2021 | -30.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More TCRX financial trends
TCRX RevenueTCRX Net incomeTCRX Net marginTCRX Gross profitTCRX Gross marginTCRX Operating incomeTCRX Operating marginTCRX Operating cash flowTCRX Free cash flowTCRX Capital expendituresTCRX Stock buybacksTCRX Dividends paidTCRX Total assetsTCRX Total liabilitiesTCRX Shareholders’ equityTCRX overview →